Precipio (PRPO) vs Personalis (PSNL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Personalis (PSNL) has outperformed Precipio (PRPO) over the past year, gaining 85.0% versus a gain of 26.4%. Over five years, PSNL leads with a -19.5% price change compared with -54.7% for PRPO. Personalis is the larger company by market cap ($1.72 billion vs $41.5 million), about 41.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRPO | PSNL |
|---|---|---|
| Share price | $23.19 | $16.06 |
| Market cap | $41.51M | $1.72B |
| 1-day change | -1.40% | +0.37% |
| YTD return | +0.91% | +101.76% |
| 1-year return | +26.38% | +85.02% |
| 5-year return | -54.71% | -19.46% |
| Forward P/E | 59.46 | — |
| EPS (TTM) | $-0.64 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $69.65M |
| Revenue growth (YoY) | — | -17.69% |
| Net income (latest FY) | — | $-81.27M |
| Gross margin | — | 22.65% |
| Operating margin | — | -126.43% |
| Net margin | — | -116.69% |
| 52-week high | $33.63 | $18.89 |
| 52-week low | $16.40 | $4.96 |
| Distance from 52-week high | -31.04% | -14.98% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | -5.54% |
| Average volume | 128.13K | 3.59M |
| Shares outstanding | 1.79M | 106.80M |
| Employees | 61 | 259 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Personalis is about 41.3 times larger than Precipio by market value ($1.72B vs $41.51M).
- PSNL has outperformed PRPO by 58.6 percentage points over the past year.
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Healthcare · Diagnostics & Research · 61 employees
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Healthcare · Diagnostics & Research · 259 employees
PRPO vs PSNL FAQ
Which is bigger, Precipio or Personalis?
Personalis (PSNL) is larger, with a market capitalization of $1.72B compared with $41.51M for Precipio (PRPO).
Which stock has performed better over the past year, PRPO or PSNL?
PSNL returned +85.02% over the past 12 months, compared with +26.38% for PRPO (price return, excluding dividends). Past performance does not predict future results.
Are Precipio and Personalis in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.